Clearing the path to lower cholesterol
Your patients with, or at high risk for, cardiovascular disease may be able to participate in the CLEAR program
The CLEAR Program includes four randomized, double-blind, placebo-controlled studies to assess the effects of bempedoic acid on endpoints related to cardiovascular disease and its associated risks. Approximately 15,000 patients from across the world will take part.
The CLEAR Program will assess the effect of bempedoic acid on the risk of major adverse cardiovascular events in patients with, or at high risk for, cardiovascular disease who are statin intolerant.
The CLEAR Program will determine whether bempedoic acid can help to lower LDL-C levels in patients with elevated LDL-C levels who are statin intolerant.
The CLEAR Wisdom Study will assess the efficacy of bempedoic acid for lowering LDL-C levels in patients with high cardiovascular risk with hyperlipidemia (with underlying heterozygous familial hypercholesterolemia …